Literature DB >> 12614511

Psychometric evaluation of the Hospital Anxiety and Depression Scale (HADS) among female cardiac patients.

Susan B. Roberts1, Dean M. Bonnici, Andrew J. Mackinnon, Marian C. Worcester.   

Abstract

OBJECTIVES: To examine the dimensionality, structure, and reliability of the HADS among female cardiac patients.
DESIGN: Data were collected by self-administered questionnaires at two times - admission to hospital and at 2-month follow-up.
METHOD: Confirmatory factor analysis was used to examine the dimensionality and structure of the HADS. Internal consistency was assessed by computing Cronbach alpha. Pearson product-moment correlation coefficients were calculated to assess test-retest reliability.
RESULTS: A two-factor model, in which the subscales were permitted to correlate, was found to provide a good fit to the scale's 14 items compared to single factor and orthogonal two-factor models. These two factors explained 41.4% of the total variance. The anxiety and depression subscales were moderately correlated (r =.60), with good internal consistency and test-retest reliability found for the subscales and total HADS scores.
CONCLUSIONS: These results provide support for the HADS as a reliable measure for the assessment of anxiety and depression symptomatology among female cardiac patients.

Entities:  

Year:  2001        PMID: 12614511     DOI: 10.1348/135910701169278

Source DB:  PubMed          Journal:  Br J Health Psychol        ISSN: 1359-107X


  17 in total

1.  New use for an old drug: oral ketamine for treatment-resistant depression.

Authors:  Kevin M Swiatek; Kim Jordan; Julie Coffman
Journal:  BMJ Case Rep       Date:  2016-08-03

2.  Anxiety, depression and psychosocial stress in patients with cardiac events.

Authors:  Anne John Michael; Saroja Krishnaswamy; Tamil Selvan Muthusamy; Khalid Yusuf; Jamaludin Mohamed
Journal:  Malays J Med Sci       Date:  2005-01

3.  Psychological correlates of quality of life in atrial fibrillation.

Authors:  Lephuong Ong; Robert Cribbie; Louise Harris; Paul Dorian; David Newman; Iqwal Mangat; Robert Nolan; Jane Irvine
Journal:  Qual Life Res       Date:  2006-07-07       Impact factor: 4.147

Review 4.  Understanding the Outcomes Measures used in Huntington Disease Pharmacological Trials: A Systematic Review.

Authors:  Noelle E Carlozzi; Angela Miciura; Nicholas Migliore; Praveen Dayalu
Journal:  J Huntingtons Dis       Date:  2014

5.  Prevalence of Symptoms of Anxiety Disorders and Depression in Cardiac Rehabilitation Patients in an Academic Hospital: a Case Study.

Authors:  Gladys Bruyninx; Jean Grenier; Paul S Greenman; Vanessa Tassé; Joseph Abdulnour; Marie Hélène Chomienne
Journal:  Psychiatr Q       Date:  2021-03

6.  Assessment of the structure of the Hospital Anxiety and Depression Scale in musculoskeletal patients.

Authors:  Julie F Pallant; Catherine M Bailey
Journal:  Health Qual Life Outcomes       Date:  2005-12-19       Impact factor: 3.186

7.  Cardiac rehabilitation with a nurse case manager (GoHeart) across local and regional health authorities improves risk factors, self-care and psychosocial outcomes. A one-year follow-up study.

Authors:  Vibeke Brogaard Hansen; Helle Terkildsen Maindal
Journal:  JRSM Cardiovasc Dis       Date:  2014-10-22

8.  Health-related quality of life and anxiety associated with childhood intermittent exotropia before and after surgical correction.

Authors:  Danyi Mao; Jing Lin; Lina Chen; Jiying Luo; Jianhua Yan
Journal:  BMC Ophthalmol       Date:  2021-06-30       Impact factor: 2.209

9.  Tobacco smoking predicts depression and poorer quality of life in heart disease.

Authors:  Lesley Stafford; Michael Berk; Henry J Jackson
Journal:  BMC Cardiovasc Disord       Date:  2013-05-24       Impact factor: 2.298

10.  An open label study of the use of EEG biofeedback using beta training to reduce anxiety for patients with cardiac events.

Authors:  Anne John Michael; Saroja Krishnaswamy; Jamaludin Mohamed
Journal:  Neuropsychiatr Dis Treat       Date:  2005-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.